Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
The Cochrane Database of Systematic Reviews
|
December 4, 2019
Parent training programmes for managing infantile colic
Morris Gordon, Jesal Gohil, Shel Sc Banks
AIDS (London, England)
|
January 28, 2026
The evolution of antiretroviral-associated drug-resistance mutations in an individual receiving dolutegravir/lamivudine
Jesal Gohil, Nicola E Mackie, Alan Winston
International Journal of STD & AIDS
|
August 20, 2024
BASHH standards for the management of sexual health in UK prisons
Jesal Gohil, Sophie Ross, Katia Prime, et al.
International Journal of STD & AIDS
|
February 5, 2014
Isolated penile Kaposi's sarcoma in a HIV-positive patient stable on treatment for three years
Dornubari Lebari, Jesal Gohil, Lipsita Patnaik, et al.
BMC Public Health
|
January 11, 2020
Is the Philippines ready for HIV self-testing?
Jesal Gohil, Emmanuel S Baja, Tyrone Reden Sy, et al.
The Lancet. Infectious Diseases
|
July 5, 2022
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis
Nicolò Girometti, Ruth Byrne, Margherita Bracchi, et al.
Nature Communications
|
January 21, 2025
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Jesper D Gunst, Jesal Gohil, Johanthan Z Li, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
The Cochrane Database of Systematic Reviews
|
December 4, 2019
Parent training programmes for managing infantile colic
Morris Gordon, Jesal Gohil, Shel Sc Banks
AIDS (London, England)
|
January 28, 2026
The evolution of antiretroviral-associated drug-resistance mutations in an individual receiving dolutegravir/lamivudine
Jesal Gohil, Nicola E Mackie, Alan Winston
International Journal of STD & AIDS
|
August 20, 2024
BASHH standards for the management of sexual health in UK prisons
Jesal Gohil, Sophie Ross, Katia Prime, et al.
International Journal of STD & AIDS
|
February 5, 2014
Isolated penile Kaposi's sarcoma in a HIV-positive patient stable on treatment for three years
Dornubari Lebari, Jesal Gohil, Lipsita Patnaik, et al.
BMC Public Health
|
January 11, 2020
Is the Philippines ready for HIV self-testing?
Jesal Gohil, Emmanuel S Baja, Tyrone Reden Sy, et al.
The Lancet. Infectious Diseases
|
July 5, 2022
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis
Nicolò Girometti, Ruth Byrne, Margherita Bracchi, et al.
Nature Communications
|
January 21, 2025
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies
Jesper D Gunst, Jesal Gohil, Johanthan Z Li, et al.
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial
Ming Jie Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
The Lancet. HIV
|
May 27, 2026
Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial
Ming J Lee, Louise-Rae Cherrill, Panagiota Zacharopoulou, et al.
Page
of 1